Common stock and warrants expected to commence trading on Nasdaq on August 26, 2021 under the ticker symbols EFTR and EFTRW SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today completed its business combination with Locust Walk Acquisition Corp. (NASDAQ: LWAC). The resulting combined company (the Company) has been renamed “eFFEC

Sometimes, it takes $1.5 billion to make "one plus one equal three." Bayer wanted to "really transform" its R&D engine under its recently installed pharma R&D leader. Meanwhile, the public markets had nothing on an acquisition deal for Vividion Therapeutics, so the biotech scrapped its IPO vision. Instead, the small California biotech is linking arms with the German Big Pharma, but at an "arm's length" so Vividion can remain independent, leaders from the companies told Fierce